|

Subcutaneous Blinatumomab Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Blincyto®

Pipeline

Phase 2: 1

Top Sponsors

  • West Virginia University1

Indications

  • Mixed Phenotype Acute Leukemia (MPAL)1
  • CD19 Positive1
  • Cancer1

Morgantown, West Virginia1 trial

Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)

West Virginia University Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.